表 2.

外周血免疫细胞与非小细胞肺癌免疫治疗反应的关系

Levels of peripheral immune cells correlated with immunotherapy response in NSCLC

Cell type	Biomarkers	Clinical benefit	Reference
ALC: absolute lymphocyte count; ANC: absolute neutrophil count; AEC: absolute eosinophil count, NLR: neutrophil-to-lymphocyte ratio; dNLR: derive neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PD-1: programmed death-1; TIM-3: T-cell immunoglobulin mucin 3; PR: partial response; SD: stable disease; cm/Eff: central memory/effector memory; TCR: T cell receptor; ICOS: inducible co-stimulator; M-MDSC: monocytic-myeloid-derived suppressor cell; Gr-MDSCs/PMN-MDSCs: granulocytic/polymorphonucear-myeloid-derived suppressor cells.
Blood routine examination	Baseline ANC < 7, 500/μL, ALC≥1, 000/μL, AEC≥150/μL, NLR < 5	OS, PFS	[27-29]
Cells	Baseline NLR < 6.4, PLR < 441.8, dNLR≤3	OS	[31, 30]
	Post-treatment NLR < 5 at week 6	OS, PFS	[32]
CD8+ T cells	High baseline expression of immune checkpoints (PD-1)	OS, PFS	[33]
	Low baseline expression of PD-1
	Decreased expression of PD-1 after treatment	OS, PFS	[35]
	Without increased expression of immune checkpoints (TIM-3+) after treatment	PFS	[36]
	High proliferation of PD-1+CD8+ T cells after anti-PD-1 therapy	PR/SD, DCB, PFS	[37, 38]
	High baseline TCR diversity in PD-1+CD8+ T cells	PFS	[39]
	Increased TCR diversity in T cells（including CD8+ T）at 2 weeks after treatment	OS	[40]
	Low baseline frequency of CD28-CD57+KLRG1+	OS	[42]
	Expression of CD28 and ICOS after anti-PD-1 therapy	PR/SD	[37]
	Lack CD28, ICOS and CD40L	PR/SD	[44]
	Higher baseline memory CD8+ T cells (CM/Eff T cell ratio)	PFS	[45]
CD4+ T cells	High baseline expression of immune checkpoints (PD-1)	PFS	[46]
	Higher baseline frequency of functional CD27-CD28-CD4+ T cells	PFS	[47]
	High frequencies of Treg cells one week after anti-PD-1 therapy	OS, PFS	[48]
NK cells	Higher frequency and overall activity of NK cells	PR, SD	[49]
	High baseline number of NK cells	OS, PFS	[33]
	Low baseline number of NK cells	OS, PFS	[34]
MDSCs	Low baseline frequency of PMN-MDSCs and M-MDSCs	OS, PFS	[50]
	Low numbers of M-MDSC 2 weeks after nivolumab therapy	OS	[51]
	High baseline levels of Gr-MDSC	OS, PFS	[52]
Combination cells	Higher baseline (%CD62LlowCD4+ T cells)2/(%Treg cells) ratio PFS and OS	OS, PFS	[53]
	Higher (%Treg cells)/(%LOX-1+ PMN-MDSCs) ratio after the first nivolumab infusion	PFS	[54]
	(%NK cells)/(%Lox1+ PMN-MDSC) ratio≥5.75）after the first cycle of anti-PD-1 therapy	ORR, OS, PFS	[55]